BridgeBio Pharma Total Liabilities 2018-2024 | BBIO

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

BridgeBio Pharma total liabilities from 2018 to 2024. Total liabilities can be defined as the total value of all possible claims against the corporation.

BridgeBio Pharma Total Liabilities 2018-2024 | BBIO

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

BridgeBio Pharma total liabilities from 2018 to 2024. Total liabilities can be defined as the total value of all possible claims against the corporation.

Related Stocks
Company Name	Market Cap
Teva Pharmaceutical Industries (TEVA)	$19.4B
Dr Reddy's Laboratories (RDY)	$11.9B
Bausch Health Cos (BHC)	$2.9B
Amphastar Pharmaceuticals (AMPH)	$2.2B
Supernus Pharmaceuticals (SUPN)	$2B
Taysha Gene Therapies (TSHA)	$506M
Personalis (PSNL)	$245M
Assembly Biosciences (ASMB)	$96M
Sol-Gel Technologies (SLGL)	$15M
Evoke Pharma (EVOK)	$6M
Teligent (TLGT)	$0M